A gene variant in CERS2 is associated with rate of increase in albuminuria in patients with diabetes from ONTARGET and TRANSCEND

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Shiffman, Dov ^a   Pare, Guillaume ^b   Oberbauer, Rainer ^c,d   Louie, Judy Z ^a   Rowland, Charles M ^a   Devlin, James J ^a   Mann, Johannes F ^e   McQueen, Matthew J ^b  

^a CELERA   (United States)

^b MCMASTER UNIVERSITY   (Canada)

^c KH Elisabethinen ^*  (Austria)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ALBUMIN; CERAMIDE SYNTHASE 2; CREATININE; GLUTAMIC ACID; PLACEBO; RAMIPRIL; SYNTHETASE; TELMISARTAN; UNCLASSIFIED DRUG; CERS2 PROTEIN, HUMAN; MEMBRANE PROTEIN; SPHINGOSINE ACYLTRANSFERASE; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGE DISTRIBUTION; AGED; ALBUMINURIA; AMINO ACID SUBSTITUTION; ANALYTICAL PARAMETERS; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CERS2 GENE; CHRONIC KIDNEY DISEASE; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; ENZYME ACTIVITY; ETHNICITY; FEMALE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GENETIC RISK; GENETIC VARIABILITY; GENOME ANALYSIS; GENOTYPE; GLOMERULUS FILTRATION RATE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; URINE ALBUMIN CREATININE RATIO; CHEMISTRY; COMPLICATION; DIABETIC NEPHROPATHY; GENETICS; MIDDLE AGED; PRINCIPAL COMPONENT ANALYSIS;

AGED; ALBUMINURIA; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MEMBRANE PROTEINS; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PRINCIPAL COMPONENT ANALYSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPHINGOSINE N-ACYLTRANSFERASE; TUMOR SUPPRESSOR PROTEINS;

EID: 84907190401     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0106631     Document Type: Article

References (24)

1. U.S. Renal Data System (2012) USRDS 2012 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases 2012; Available: http://www.usrds.org/atlas12.aspx. Accessed: 2014 Jan 10.
2. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, et al. (2003) Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int 63: 225-232.
3. Mann JF, Gerstein HC, Yi QL, Lonn EM, Hoogwerf BJ, et al. (2003). Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. J Am Soc Nephrol 14: 641-647.
4. Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR (2006) Risk factors for renal dysfunction in type 2 diabetes UK Prospective Diabetes Study 74. Diabetes 55: 1832-1839.
5. Köttgen A, Pattaro C, Böger CA, Fuchsberger C, Olden M, et al. (2010) New loci associated with kidney function and chronic kidney disease. Nat Genet 42: 376-384.
6. Böger CA, Gorski M, Li M, Hoffmann MM, Huang C, et al. (2011) Association of eGFR-Related Loci Identified by GWAS with Incident CKD and ESRD. PLoS Genet 7: e1002292
7. Deshmukh HA, Palmer CN, Morris AD, Colhoun HM (2013) Investigation of known estimated glomerular filtration rate loci in patients with Type 2 diabetes. Diabet Med 30: 1230-1235.
8. Ellis JW, Chen MH, Foster MC, Liu CT, Larson MG, et al. (2012). Validated SNPs for eGFR and their associations with albuminuria. Hum Mol Genet 21: 3293-3298.
9. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, et al. (2004) ONTARGET/TRANSCEND Investigators: Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 148: 52-61.
10. Yusuf S, Teo K, Anderson C, Pogue J, Dyal L, et al. (2008) Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. Lancet 372: 1174-1183.
11. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. (2008) Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 358: 1547-1559.
12. Voight BF, Kang HM, Ding J, Palmer CD, Sidore C, et al. (2012) The metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits. PLoS Genet 8: e1002793.
13. Fellay J, Thompson AJ, Ge D, Gumbs CE, Urban TJ, et al. (2010) ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 464: 405-408.
14. Shiffman D, Ellis SG, Rowland CM, Malloy MJ, Luke MM, et al. (2005) Identification of four gene variants associated with myocardial infarction. Am J Hum Genet 77: 596-605.
15. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, et al. (2006) Principal components analysis corrects for stratification in genome-wide association studies Nat Genet 38: 904-909.
16. DerSimonian R, Laird N (1986) Meta-Analysis in Clinical Trials Controlled Clinical Trials 7: 177-188.
17. Pinheiro JC, Bates DM, DebRoy S, Sarkar D, R Development Core Team (2012). nlme: Linear and Nonlinear Mixed Effects Models. R package version 3.1-103.
18. Pinheiro JC, Bates DM (2000) Mixed-Effects Models in S and S-PLUS, New York: Springer-Verlag New York, Inc.
19. Laird NM, Ware JH (1982) Random-Effects Models for Longitudinal Data Biometrics, 38, 963-974.
20. Böger CA, Chen MH, Tin A, Olden M, Köttgen A, et al. (2011) CUBN is a gene locus for albuminuria. J Am Soc Nephrol 22: 555-570.
21. Hannun YA, Obeid LM (2011) Many ceramides. J Biol Chem 286: 27855-27862.
22. Laviad EL, Albee L, Pankova-Kholmyansky I, Epstein S, Park H, et al. (2008) Characterization of ceramide synthase 2: tissue distribution, substrate specificity, and inhibition by sphingosine 1-phosphate. J Biol Chem 283: 5677-5684.
23. Imgrund S, Hartmann D, Farwanah H, Eckhardt M, Sandhoff R, et al. (2009) Adult ceramide synthase 2 (CERS2)-deficient mice exhibit myelin sheath defects, cerebellar degeneration, and hepatocarcinomas. J Biol Chem 284: 33549-33560.
24. Pewzner-Jung Y, Brenner O, Braun S, Laviad EL, Ben-Dor S, et al. (2010) A critical role for ceramide synthase 2 in liver homeostasis: II. insights into molecular changes leading to hepatopathy. J Biol Chem 285: 10911-10923.